

May 31, 2016

(Electronically Filed)  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P O Box 1450  
Alexandria, VA 22313-1450

*Inter Partes* Review IPR2016-01095 (U.S. Patent No. 6,667,061)  
Exhibit Cover Letter Per 37 C.F.R. § 42.6(e)(4)(ii)

Dear Patent Trial and Appeal Board:

This transmittal letter identifies Exhibits 1001-1008, 1010, 1014-1023, being filed concurrently with the present Petition for *Inter Partes* Review. Pursuant to 37 C.F.R. § 42.6(e)(4)(ii), the Certificate of Service attached to the end of the Petition for *Inter Partes* Review filed herewith, incorporates Exhibits 1001-1008, 1010, 1014-1023, as listed below:

Exhibit #	Reference
1001	U.S. Patent No. 6,667,061 (“the ’061 Patent”)
1002	Declaration of Dr. Patrick P. DeLuca
1003	<i>Curriculum Vitae</i> of Dr. Patrick P. DeLuca
1004	International Publication No. WO 99/01114 (“Goldenheim”)
1005	International Publication No. WO 95/13799 (“Ramstack”)
1006	U.S. Pharmacopeia Entry re: CMC, viscosity pp.274-75, 1840 (1994)
1007	EP Pharmacopoeia Entry re: CMC pp.547-48 (3d ed. 1997)
1008	Handbook of Pharmaceutical Excipients pp.78-81, 135-38, 294-98, 329-330, 375-78, 420-21, 439-42, 477-80, 481-82 (2nd ed. 1994)
1009	Intentionally left blank
1010	U.S. Patent No. 5,656,299 (“Kino”)
1011	Intentionally left blank
1012	Intentionally left blank
1013	Intentionally left blank
1014	Herbert A. Lieberman <i>et al.</i> (eds.), <i>Pharmaceutical Dosage Forms: Disperse Systems</i> , Vol.2, pp.26-35, 40, 43-46, 261, 285-318 (2nd ed. rev. expanded 1996)

Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
May 31, 2016  
Page 2

Exhibit #	Reference
1015	U.S. Patent No. 6,495,164 (“the ’164 Patent”)
1016	Serial No. 10/259,949, Office Action, Apr. 9, 2003
1017	Serial No. 10/259,949, Applicants’ Resp., May 14, 2003
1018	Serial No. 09/577,875, Declaration of Mark A. Tracy, May 17, 2002
1019	Serial No. 10/259,949, Notice of Allowability, July 24, 2003
1020	Kenneth E. Avis <i>et al.</i> (eds.), 1 (Chs.2, 4, 5) <i>Pharmaceutical Dosage Forms: Parenteral Medications</i> 17-25, 115-16, 140-43, 150-51, 173-75, 190-212 (2nd ed. rev. expanded Marcel Dekker, Inc. 1992)
1021	Leon Lachman, PhD <i>et al.</i> , <i>The Theory and Practice of Industrial Pharmacy</i> 642-44, 783-84 (Lea & Febiger 3rd ed. 1986)
1022	Herbert A. Lieberman <i>et al.</i> , <i>Pharmaceutical Dosage Forms: Disperse Systems</i> , Vol.1, pp.287-313 (2nd ed. rev. expanded 1996)
1023	Orange Book entries for RISPERDAL®

Respectfully submitted,

LERNER, DAVID, LITTENBERG,  
KRUMHOLZ & MENTLIK, LLP

William L. Mentlik  
Reg. No. 27,108

WLM/dmf